NESS ZIONA, Israel – February 6, 2018 – Mapi Pharma Ltd., a fully integrated, clinical late stage biopharmaceutical company, announced today that it will host a Key Opinion Leader (KOL) luncheon on its GA Depot, a novel long-acting depot formulation of glatiramer acetate for multiple sclerosis (MS) on Tuesday, February 13th in New York City.
The meeting will feature a presentation by Dr. Carlo Tornatore, MD, Georgetown University Medical Center, who will discuss the current treatment landscape, as well as the unmet medical need for treating patients with MS. Dr. Tornatore will be available to answer questions at the conclusion of the event.
Mapi Pharma’s CEO and Chairman Ehud Marom, together with top management, will provide an overview of the company’s positioning in the MS market, including a presentation on their lead product candidate, GA Depot, a glatiramer acetate treatment administered once every four weeks for relapsing MS patients. Glatiramer acetate, marketed as Copaxone®, is currently the leading drug for patients with MS in the US. Mapi Pharma has completed an open-label Phase II clinical trial and is preparing to submit an IND application to the FDA, for a pivotal Phase III clinical trial to support a marketing application under the 505(b)(2) regulatory pathway.
Carlo Tornatore, MD, is Professor and Chairman of Neurology at Georgetown University Medical Center as well as Director of the Multiple Sclerosis Patient Centered Specialty Practice at Medstar Georgetown University Hospital in Washington, DC. He earned his master’s degree in physiology at Georgetown University and his medical degree at Georgetown University Medical School. He completed his internship at Providence Hospital and his residency in neurology at Georgetown University Hospital. His fellowship was completed at the National Institute for Neurologic Disorders and Stroke at the National Institutes of Health in the Laboratory of Molecular Medicine and Neuroscience in Bethesda, MD. Dr. Tornatore is a member of the American Academy of Neurology and American Society for Neural Transplantation. His research interests include multiple sclerosis treatment, neuroimmunology, neuro-AIDS, and infectious diseases of the central nervous system, for which he has published a wide variety of articles and book chapters. In addition, he is a reviewer for several journals including Annals of Neurology, Neurology, and Medical Virology.
This event is intended for institutional investors, sell-side analysts, investment bankers, and business development professionals only. Please RSVP in advance if you plan to attend, as space is limited. For those who are unable to attend in person, a live webcast and replay will be accessible here.
About Mapi Pharma
Mapi is a clinical stage pharmaceutical company, engaged in the development of high barrier-to-entry and high added-value life cycle management (LCM) products that target large markets, as well as generic drugs that include complex active pharmaceutical ingredients (APIs) and formulations. The GA Depot injection, administered once every four weeks, is the first in a series of depot long-acting injections in the company’s pipeline, for the treatment of MS. The product is an LCM version of Copaxone® (glatiramer acetate (GA) injection) which requires an injection daily or every other day. Mapi is built on strong chemical and pharmaceutical R&D capabilities as well as a deep understanding of the global market and of regulatory needs, together with the ability to foster local cooperation and enduring relationships in all of the countries in which it operates. Mapi is headquartered in Israel, with R&D facilities in Israel and China, and an API production facility in the Neot–Hovav Eco Industrial Park south of Beersheba, Israel. Mapi has a strong IP position, filing numerous patent applications for APIs and formulations. For more information, please visit: www.mapi-pharma.com.
Vice President, Corporate Development
+972 52 6080297
LifeSci Advisors, LLC